{"success":true,"data":{"pressRelease":{"id":"174590","rtpr_id":"nBw6vgvsda-20261020","ticker":"VRTX","exchange":"NASDAQ","all_tickers":["VRTX"],"title":"Vertex Appoints Daniel Brennan to its Board of Directors","author":"Business Wire","published_at":"2026-10-20T20:05:00.631Z","article_body":"Vertex Appoints Daniel Brennan to its Board of Directors\n\nVertex Pharmaceuticals Incorporated\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vrtx.com%2F&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=Vertex+Pharmaceuticals+Incorporated&index=1&md5=67171231d3fd815a2b257215d65f8c33)\n(Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its\nBoard of Directors as an independent director. Mr. Brennan has more than 35\nyears of experience in finance roles at leading healthcare companies,\nincluding more than 25 years at Boston Scientific Corporation, a medical\ndevice and healthcare technology company. Mr. Brennan retired last year from\nserving as Boston Scientific’s Executive Vice President, Chief Financial\nOfficer, where he had responsibility for all global finance functions and\ncorporate business development.\n\n“Dan’s extensive financial leadership experience and deep understanding of\nglobal healthcare businesses will bring an important perspective to the Vertex\nBoard,” said Jeffrey Leiden, M.D., Ph.D., Executive Chairman of Vertex.\n“His experience navigating periods of high growth and strategic expansion\nwill be especially valuable as Vertex continues to expand, diversify and\ninvest in innovation so we can make a meaningful impact for many more\npatients.”\n\n“Vertex’s track record demonstrates what is possible when bold science is\nsupported by a clear strategy and strong execution,” said Mr. Brennan. “I\nam honored to join the Board and look forward to helping the company extend\nits impact to more patients while sustaining the capabilities and investments\nneeded for long-term success.”\n\nMr. Brennan serves on the Boards of Directors of Waters Corporation and\nMadrigal Pharmaceuticals, where he also serves as the Chair of the Audit\nCommittee. He holds a B.S. in finance and investments and an M.B.A. from\nBabson College and is also a certified public accountant.\n\nIn connection with the appointment of Mr. Brennan, the size of the Vertex\nBoard was increased from 10 to 11 members.\n\nAbout Vertex\n\nVertex is a global biotechnology company that invests in scientific innovation\nto create transformative medicines for people with serious diseases and\nconditions. The company has approved therapies for cystic fibrosis, sickle\ncell disease, transfusion-dependent beta thalassemia, acute pain and\nacromegaly, and it continues to advance clinical and research programs in\nthese areas. Vertex also has a robust clinical pipeline of investigational\ntherapies across a range of modalities in other serious diseases where it has\ndeep insight into causal human biology, including IgA nephropathy, neuropathic\npain, APOL1-mediated kidney disease, primary membranous nephropathy,\ncongenital adrenal hyperplasia, adrenocorticotropic hormone (ACTH)-dependent\nCushing's syndrome, autosomal dominant polycystic kidney disease, type 1\ndiabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.\n\nVertex was founded in 1989 and has its global headquarters in Boston, with\ninternational headquarters in London. Additionally, the company has research\nand development sites and commercial offices in North America, Europe,\nAustralia, Latin America and the Middle East. Vertex is consistently\nrecognized as one of the industry's top places to work, including 16\nconsecutive years on Science magazine's Top Employers list and one of\nFortune’s 100 Best Companies to Work For. For company updates and to learn\nmore about Vertex's history of innovation, visit www.vrtx.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vrtx.com&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=www.vrtx.com&index=2&md5=85cbbdce971e7237596a7a8e78547bc3)\nor follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2FVertex-Pharmaceuticals&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=LinkedIn&index=3&md5=90b49de074f46106b369151d76d89f6a)\n, Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FVertexPharmaInc&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=Facebook&index=4&md5=27820795eaa720092738fc0a0601b61c)\n, Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fvertexpharmaceuticals&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=Instagram&index=5&md5=4d5f003089994c9c0eeacce6a74ba69a)\n, YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2F%40Vertex-Pharmaceuticals&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=YouTube&index=6&md5=5e4911bac26d7bc5263da534ef29b3c1)\nand X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.x.com%2FVertexPharma&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=X&index=7&md5=09cfefbcb444be521e34d99bc61bdef9)\n.\n\n(VRTX-GEN)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261019180482/en/\n(https://www.businesswire.com/news/home/20261019180482/en/)\n\nInvestors: \n\nInvestorInfo@vrtx.com (mailto:InvestorInfo@vrtx.com) or\n\n+1 617-341-6108\n\nMedia: \n\nmediainfo@vrtx.com (mailto:mediainfo@vrtx.com) or\n\n+1 617-341-6992\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw6vgvsda-20261020","title":"Vertex Appoints Daniel Brennan to its Board of Directors","author":"Business Wire","ticker":"VRTX","created":"2026-10-20T20:05:00.631Z","tickers":["VRTX"],"exchange":"NASDAQ","article_body":"Vertex Appoints Daniel Brennan to its Board of Directors\n\nVertex Pharmaceuticals Incorporated\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vrtx.com%2F&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=Vertex+Pharmaceuticals+Incorporated&index=1&md5=67171231d3fd815a2b257215d65f8c33)\n(Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its\nBoard of Directors as an independent director. Mr. Brennan has more than 35\nyears of experience in finance roles at leading healthcare companies,\nincluding more than 25 years at Boston Scientific Corporation, a medical\ndevice and healthcare technology company. Mr. Brennan retired last year from\nserving as Boston Scientific’s Executive Vice President, Chief Financial\nOfficer, where he had responsibility for all global finance functions and\ncorporate business development.\n\n“Dan’s extensive financial leadership experience and deep understanding of\nglobal healthcare businesses will bring an important perspective to the Vertex\nBoard,” said Jeffrey Leiden, M.D., Ph.D., Executive Chairman of Vertex.\n“His experience navigating periods of high growth and strategic expansion\nwill be especially valuable as Vertex continues to expand, diversify and\ninvest in innovation so we can make a meaningful impact for many more\npatients.”\n\n“Vertex’s track record demonstrates what is possible when bold science is\nsupported by a clear strategy and strong execution,” said Mr. Brennan. “I\nam honored to join the Board and look forward to helping the company extend\nits impact to more patients while sustaining the capabilities and investments\nneeded for long-term success.”\n\nMr. Brennan serves on the Boards of Directors of Waters Corporation and\nMadrigal Pharmaceuticals, where he also serves as the Chair of the Audit\nCommittee. He holds a B.S. in finance and investments and an M.B.A. from\nBabson College and is also a certified public accountant.\n\nIn connection with the appointment of Mr. Brennan, the size of the Vertex\nBoard was increased from 10 to 11 members.\n\nAbout Vertex\n\nVertex is a global biotechnology company that invests in scientific innovation\nto create transformative medicines for people with serious diseases and\nconditions. The company has approved therapies for cystic fibrosis, sickle\ncell disease, transfusion-dependent beta thalassemia, acute pain and\nacromegaly, and it continues to advance clinical and research programs in\nthese areas. Vertex also has a robust clinical pipeline of investigational\ntherapies across a range of modalities in other serious diseases where it has\ndeep insight into causal human biology, including IgA nephropathy, neuropathic\npain, APOL1-mediated kidney disease, primary membranous nephropathy,\ncongenital adrenal hyperplasia, adrenocorticotropic hormone (ACTH)-dependent\nCushing's syndrome, autosomal dominant polycystic kidney disease, type 1\ndiabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.\n\nVertex was founded in 1989 and has its global headquarters in Boston, with\ninternational headquarters in London. Additionally, the company has research\nand development sites and commercial offices in North America, Europe,\nAustralia, Latin America and the Middle East. Vertex is consistently\nrecognized as one of the industry's top places to work, including 16\nconsecutive years on Science magazine's Top Employers list and one of\nFortune’s 100 Best Companies to Work For. For company updates and to learn\nmore about Vertex's history of innovation, visit www.vrtx.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vrtx.com&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=www.vrtx.com&index=2&md5=85cbbdce971e7237596a7a8e78547bc3)\nor follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2FVertex-Pharmaceuticals&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=LinkedIn&index=3&md5=90b49de074f46106b369151d76d89f6a)\n, Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FVertexPharmaInc&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=Facebook&index=4&md5=27820795eaa720092738fc0a0601b61c)\n, Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fvertexpharmaceuticals&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=Instagram&index=5&md5=4d5f003089994c9c0eeacce6a74ba69a)\n, YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2F%40Vertex-Pharmaceuticals&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=YouTube&index=6&md5=5e4911bac26d7bc5263da534ef29b3c1)\nand X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.x.com%2FVertexPharma&esheet=54624626&newsitemid=20261019180482&lan=en-US&anchor=X&index=7&md5=09cfefbcb444be521e34d99bc61bdef9)\n.\n\n(VRTX-GEN)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261019180482/en/\n(https://www.businesswire.com/news/home/20261019180482/en/)\n\nInvestors: \n\nInvestorInfo@vrtx.com (mailto:InvestorInfo@vrtx.com) or\n\n+1 617-341-6108\n\nMedia: \n\nmediainfo@vrtx.com (mailto:mediainfo@vrtx.com) or\n\n+1 617-341-6992\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-20T20:05:00.804401096Z","server_sent_at_ms":1792526700804},"received_at":"2026-10-20T20:05:00.855Z","source_url":"https://www.businesswire.com/news/home/20261019180482/en/"},"analysis":{"id":"162647","press_release_id":"174590","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"Vertex Pharmaceuticals appointed Daniel Brennan to its Board of Directors as an independent director, expanding the board from 10 to 11 members.\n\nBrennan retired last year as EVP and CFO of Boston Scientific after more than 25 years there, bringing over 35 years of healthcare finance experience.\n\nHe also serves on the boards of Waters Corporation and Madrigal Pharmaceuticals, chairing Madrigal's audit committee.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine governance update -- former Boston Scientific CFO adds audit/finance depth to Vertex board."},"keyFigures":{"customDimensions":{"board_size_after":11,"board_size_before":10}},"quotedText":"Dan's extensive financial leadership experience and deep understanding of global healthcare businesses will bring an important perspective to the Vertex Board","namedEntities":{"people":[{"name":"Daniel Brennan","role":"new independent director; former EVP & CFO of Boston Scientific"},{"name":"Jeffrey Leiden, M.D., Ph.D.","role":"Executive Chairman of Vertex"}],"products":[],"companies":[{"name":"Vertex Pharmaceuticals Incorporated","ticker":"VRTX","relationship":"filer"},{"name":"Boston Scientific Corporation","relationship":"Brennan's former employer (25+ years)"},{"name":"Waters Corporation","relationship":"other board seat of Brennan"},{"name":"Madrigal Pharmaceuticals","relationship":"other board seat of Brennan; audit committee chair"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine board appointment adding an independent director with CFO experience; board expands from 10 to 11. No change in strategy, governance, or operations."},"tickerRelevance":{"others":[],"primary":"VRTX"},"globalImportance":12,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"routine-board-appointment","householdBrandBoost":false,"retailFavoriteBoost":false}},"event_type":"board_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Vertex Pharmaceuticals appointed Daniel Brennan to its Board of Directors as an independent director, expanding the board from 10 to 11 members.\n\nBrennan retired last year as EVP and CFO of Boston Scientific after more than 25 years there, bringing over 35 years of healthcare finance experience.\n\nHe also serves on the boards of Waters Corporation and Madrigal Pharmaceuticals, chairing Madrigal's audit committee.","key_figures":{"customDimensions":{"board_size_after":11,"board_size_before":10}},"named_entities":{"people":[{"name":"Daniel Brennan","role":"new independent director; former EVP & CFO of Boston Scientific"},{"name":"Jeffrey Leiden, M.D., Ph.D.","role":"Executive Chairman of Vertex"}],"products":[],"companies":[{"name":"Vertex Pharmaceuticals Incorporated","ticker":"VRTX","relationship":"filer"},{"name":"Boston Scientific Corporation","relationship":"Brennan's former employer (25+ years)"},{"name":"Waters Corporation","relationship":"other board seat of Brennan"},{"name":"Madrigal Pharmaceuticals","relationship":"other board seat of Brennan; audit committee chair"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-20T20:05:12.455Z","global_importance":12,"audience_relevance":25,"importance_components":{"tickerTier":"large-cap","eventGravity":"routine-board-appointment","householdBrandBoost":false,"retailFavoriteBoost":false}},"durationMs":4078,"modelName":"glm-5.3-flashx"}}